These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 21729110)

  • 41. Combining CDP-choline and galantamine: Effects of a selective α7 nicotinic acetylcholine receptor agonist strategy on P50 sensory gating of speech sounds in healthy volunteers.
    Choueiry J; Blais CM; Shah D; Smith D; Fisher D; Illivitsky V; Knott V
    J Psychopharmacol; 2019 Jun; 33(6):688-699. PubMed ID: 30920339
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Advances in the In vitro and In vivo pharmacology of Alpha4beta2 nicotinic receptor positive allosteric modulators.
    Wilkerson JL; Deba F; Crowley ML; Hamouda AK; McMahon LR
    Neuropharmacology; 2020 May; 168():108008. PubMed ID: 32113032
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Restoring long-term potentiation impaired by amyloid-beta oligomers: comparison of an acetylcholinesterase inhibitior and selective neuronal nicotinic receptor agonists.
    Kroker KS; Moreth J; Kussmaul L; Rast G; Rosenbrock H
    Brain Res Bull; 2013 Jul; 96():28-38. PubMed ID: 23639920
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Agonist activation of alpha7 nicotinic acetylcholine receptors via an allosteric transmembrane site.
    Gill JK; Savolainen M; Young GT; Zwart R; Sher E; Millar NS
    Proc Natl Acad Sci U S A; 2011 Apr; 108(14):5867-72. PubMed ID: 21436053
    [TBL] [Abstract][Full Text] [Related]  

  • 45. α7 nicotinic acetylcholine receptors: a therapeutic target in the structure era.
    Taly A; Charon S
    Curr Drug Targets; 2012 May; 13(5):695-706. PubMed ID: 22300037
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Significance of the nicotinic alpha7 receptor in cognition and antipsychotic-like behavior in the rat.
    Wadenberg MG; Manetti D; Romanelli MN; Arias HR
    Behav Brain Res; 2017 Aug; 333():129-134. PubMed ID: 28684359
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Beyond acetylcholinesterase inhibitors for treating Alzheimer's disease: α7-nAChR agonists in human clinical trials.
    Russo P; Del Bufalo A; Frustaci A; Fini M; Cesario A
    Curr Pharm Des; 2014; 20(38):6014-21. PubMed ID: 24641224
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Contrasting properties of α7-selective orthosteric and allosteric agonists examined on native nicotinic acetylcholine receptors.
    Gill JK; Chatzidaki A; Ursu D; Sher E; Millar NS
    PLoS One; 2013; 8(1):e55047. PubMed ID: 23383051
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of α7 nicotinic acetylcholine receptor agonists on antipsychotic efficacy in a preclinical mouse model of psychosis.
    Kohlhaas KL; Bitner RS; Gopalakrishnan M; Rueter LE
    Psychopharmacology (Berl); 2012 Apr; 220(4):823-33. PubMed ID: 22038534
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The combination of memantine and galantamine improves cognition in rats: The synergistic role of the α7 nicotinic acetylcholine and NMDA receptors.
    Nikiforuk A; Potasiewicz A; Kos T; Popik P
    Behav Brain Res; 2016 Oct; 313():214-218. PubMed ID: 27435422
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nicotine improves probabilistic reward learning in wildtype but not alpha7 nAChR null mutants, yet alpha7 nAChR agonists do not improve probabilistic learning.
    Milienne-Petiot M; Higa KK; Grim A; Deben D; Groenink L; Twamley EW; Geyer MA; Young JW
    Eur Neuropsychopharmacol; 2018 Nov; 28(11):1217-1231. PubMed ID: 30213668
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chemical conversion of nicotinamide into type I positive allosteric modulator of α7 nAChRs.
    Li X; Xie W; Wang X; Huang Z; Bian X; Wang K; Sun Q
    Bioorg Med Chem Lett; 2019 Aug; 29(15):1928-1933. PubMed ID: 31153804
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Muscarinic and nicotinic acetylcholine receptor agonists: current scenario in Alzheimer's disease therapy.
    Verma S; Kumar A; Tripathi T; Kumar A
    J Pharm Pharmacol; 2018 Aug; 70(8):985-993. PubMed ID: 29663387
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nicotine activates cell-signaling pathways through muscle-type and neuronal nicotinic acetylcholine receptors in non-small cell lung cancer cells.
    Carlisle DL; Liu X; Hopkins TM; Swick MC; Dhir R; Siegfried JM
    Pulm Pharmacol Ther; 2007; 20(6):629-41. PubMed ID: 17015027
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Stimulation of the alpha4beta2 nicotinic receptor by 5-I A-85380 improves auditory gating in DBA/2 mice.
    Wildeboer KM; Stevens KE
    Brain Res; 2008 Aug; 1224():29-36. PubMed ID: 18582447
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Modeling subtype-selective agonists binding with alpha4beta2 and alpha7 nicotinic acetylcholine receptors: effects of local binding and long-range electrostatic interactions.
    Huang X; Zheng F; Chen X; Crooks PA; Dwoskin LP; Zhan CG
    J Med Chem; 2006 Dec; 49(26):7661-74. PubMed ID: 17181149
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Positive allosteric modulation of alpha7 neuronal nicotinic acetylcholine receptors: lack of cytotoxicity in PC12 cells and rat primary cortical neurons.
    Hu M; Gopalakrishnan M; Li J
    Br J Pharmacol; 2009 Dec; 158(8):1857-64. PubMed ID: 20050184
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Discovery of a novel alpha-7 nicotinic acetylcholine receptor agonist series and characterization of the potent, selective, and orally efficacious agonist 5-(4-acetyl[1,4]diazepan-1-yl)pentanoic acid [5-(4-methoxyphenyl)-1H-pyrazol-3-yl] amide (SEN15924, WAY-361789).
    Zanaletti R; Bettinetti L; Castaldo C; Cocconcelli G; Comery T; Dunlop J; Gaviraghi G; Ghiron C; Haydar SN; Jow F; Maccari L; Micco I; Nencini A; Scali C; Turlizzi E; Valacchi M
    J Med Chem; 2012 May; 55(10):4806-23. PubMed ID: 22468936
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease.
    Bitner RS; Bunnelle WH; Decker MW; Drescher KU; Kohlhaas KL; Markosyan S; Marsh KC; Nikkel AL; Browman K; Radek R; Anderson DJ; Buccafusco J; Gopalakrishnan M
    J Pharmacol Exp Ther; 2010 Sep; 334(3):875-86. PubMed ID: 20504913
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Selective alpha7 nicotinic acetylcholine receptor agonists worsen disease in experimental colitis.
    Snoek SA; Verstege MI; van der Zanden EP; Deeks N; Bulmer DC; Skynner M; Lee K; Te Velde AA; Boeckxstaens GE; de Jonge WJ
    Br J Pharmacol; 2010 May; 160(2):322-33. PubMed ID: 20423343
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.